By Hendra Lukman 
Researchers at Duke University have shown that blocking an enzyme involved in iron regulation not only kills multiple myeloma cancer cells, but also increases the effectiveness of current therapies against the disease. This groundbreaking discovery, published on September 12 in the esteemed journal Blood, offers a promising new avenue for treating a relentless and often drug-resistant blood cancer. The findings suggest a significant shift in our understanding of how multiple myeloma cells survive and thrive, and importantly, how they can be therapeutically targeted.
The Persistent Challenge of Multiple Myeloma
Multiple myeloma (MM) stands as a formidable opponent in the realm of hematologic malignancies. It originates from plasma cells, a vital component of the immune system responsible for producing antibodies to combat infections. However, in MM, these plasma cells undergo malignant transformation, proliferating uncontrollably within the bone marrow. This uncontrolled growth leads to a cascade of devastating consequences: healthy blood-forming cells are displaced, the body’s ability to fight infection is compromised, and abnormal antibodies, often referred to as M-proteins, are produced in excess. These M-proteins can accumulate in organs, leading to severe kidney damage, bone fragility and pain, and a general weakening of the immune system.
Globally, multiple myeloma accounts for approximately 10 percent of all diagnoses of blood cancers. While significant advancements have been made in developing targeted therapies and improving patient outcomes over the past decade, the disease remains incurable. A persistent and growing concern is the increasing incidence of relapsed disease and the emergence of drug-resistant MM, which severely limit treatment options and prognosis for a substantial number of patients. The journey for many MM patients involves cycles of treatment, remission, and eventual relapse, underscoring the urgent need for novel therapeutic strategies that can overcome resistance mechanisms.
Unraveling the Mystery of Cancer Cell Survival: The Role of Iron and Ferroptosis
The precise etiology of multiple myeloma remains an active area of research. However, a consistent observation in MM cells has been the suppression of a natural cellular process known as ferroptosis. Ferroptosis is a form of programmed cell death characterized by the accumulation of excess iron within cells, leading to lipid peroxidation and oxidative damage to cell membranes. This damage ultimately triggers the cell’s self-destruction. In healthy cells, this mechanism acts as a crucial safeguard against cellular dysfunction.
In stark contrast, multiple myeloma cells appear to have evolved a remarkable ability to circumvent ferroptosis. They often exhibit significantly higher iron levels than normal cells, a condition that would typically be lethal. Yet, instead of succumbing to iron overload, these cancer cells not only survive but appear to thrive, utilizing the accumulated iron to fuel their rapid proliferation. This paradoxical resilience has long puzzled researchers, as the mechanisms by which MM cells evade ferroptosis remained largely obscure.
"Cancer cells live like there is no tomorrow," stated Mikhail Nikiforov, a professor of pathology and biomedical engineering at Duke University and a lead author on the study. "They accumulate iron at levels that would normally be toxic and tear cells apart, but that wasn’t what we observed. Instead, these cancer cells adapted to resist the type of cell death triggered by iron overload, and the mechanisms behind this suppression were largely unknown." This observation formed the critical question that propelled Nikiforov and his team’s research forward.
Identifying the Key Regulator: STK17B as the Ferroptosis Gatekeeper
After years of dedicated investigation, Nikiforov and a multidisciplinary team of collaborators at Duke University have identified a crucial enzyme, kinase STK17B, as a pivotal player in suppressing ferroptosis within multiple myeloma cells. STK17B is a protein kinase typically involved in regulating cell death pathways and T-cell activation, fundamental processes in maintaining cellular homeostasis and immune responses. However, the Duke team’s research revealed an unexpected and critical role for STK17B in multiple myeloma: maintaining iron balance within the cell by orchestrating the expression of proteins that either promote (pro-ferroptotic) or inhibit (anti-ferroptotic) ferroptosis.
The study’s findings indicate that elevated levels of STK17B are not merely a characteristic of MM cells but are also a significant prognostic indicator. "Elevated levels of STK17B are associated with poor overall survival in MM patients," Nikiforov elaborated. This correlation highlights the clinical relevance of the enzyme. Furthermore, the research observed that STK17B expression is particularly pronounced in cases of relapsed multiple myeloma, a finding that strongly underscores its direct involvement in mediating resistance to conventional therapies. This suggests that STK17B acts as a critical shield, protecting the cancer cells from the lethal consequences of their iron dependency.
A Novel Therapeutic Approach: Inhibiting STK17B to Reawaken Cell Death
The identification of STK17B as a key regulator of ferroptosis suppression opened the door to a novel therapeutic strategy. The research team utilized a specialized compound developed by Timothy Willson, the Harold Kohn Distinguished Professor in Open Science Drug Discovery at the UNC Eshelman School of Pharmacy. This compound was specifically designed to inhibit the activity of STK17B.
By blocking STK17B’s control over iron metabolism, the researchers were able to effectively reactivate the ferroptosis pathway in multiple myeloma cells. This reactivation led to increased oxidative stress and ultimately, cell death. Crucially, the study also revealed a synergistic effect: inhibiting STK17B not only killed cancer cells directly but also significantly enhanced the sensitivity of these cells to existing, conventional multiple myeloma therapies. This means that by targeting STK17B, existing treatments, which might otherwise be rendered ineffective by drug resistance, could regain their potency.
Preclinical Validation: Promising Results in Animal Models
To validate their findings in a more complex biological system, Nikiforov’s team proceeded with preclinical studies using mouse models of multiple myeloma. They administered an orally available version of the STK17B inhibitor to these models. The results were highly encouraging. The compound successfully induced ferroptosis in the cancer cells by increasing their iron uptake, a mechanism that directly counteracted the cancer’s ability to manage iron overload. Furthermore, this intervention led to a significant reduction in tumor growth, demonstrating the therapeutic efficacy of the STK17B inhibitor in vivo.
"These findings establish that STK17B is a critical safeguard protecting MM cells from the toxic consequences of their iron independence," Nikiforov concluded. "Inhibiting this kinase holds much promise as a therapeutic strategy." The success in preclinical models provides a strong foundation for the potential translation of this research into human clinical trials.
Broader Implications and Future Directions
The implications of this research extend far beyond multiple myeloma. The fundamental mechanism of ferroptosis and its dysregulation is implicated in a wide array of diseases, including neurodegenerative disorders, ischemia-reperfusion injury, and various other cancers. The Duke team is already looking ahead to explore the broader applicability of their findings.
"Many other types of cancer cells are also resistant to ferroptosis," Nikiforov noted. "We’re curious to see how this inhibitor could improve therapies for other tumors outside of multiple myeloma." This suggests that the STK17B inhibitor could potentially serve as a versatile therapeutic agent, applicable to a broader spectrum of cancers characterized by ferroptosis resistance.
The team has taken proactive steps toward translating this promising research into a tangible therapy. They have filed a provisional patent based on their findings, with the ultimate goal of commercializing the developed therapy. Beyond patenting, they are also focused on optimizing the formulation of the inhibitor to ensure its safety, efficacy, and ease of administration in future human trials. The next crucial phase will involve rigorous clinical testing to assess the inhibitor’s performance in human patients, starting with Phase 1 trials to evaluate safety and dosage.
Funding and Collaboration: The Pillars of Scientific Advancement
This significant scientific endeavor was made possible through substantial support from various governmental and private funding bodies. Key contributions came from the National Institutes of Health (NIH) and the National Cancer Institute (NCI) through grants NCI R01CA264984 (awarded to M.A.N.), NCI R21CA267275 and 17R21CA280499 (awarded to Y. K.), and NHLBI R01HL168492 (awarded to E.A.L.). Additional support was provided by the Duke Cancer Institute (NCI P30CA014236) and the Paula and Rodger Riney Foundation (L.H.B.).
Furthermore, the Structural Genomics Consortium (SGC), a registered charity (no: 1097737), played a vital role. The SGC receives funding from a consortium of pharmaceutical and governmental partners, including Bayer AG, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Genome Canada, through Ontario Genomics Institute [OGI-196], EU/EFPIA/OICR/McGill/KTH/Diamond Innovative Medicines Initiative 2 Joint Undertaking [EUbOPEN grant 875510], Janssen, Merck KGaA (also known as EMD in Canada and the US), Pfizer, and Takeda. Funding for this particular project was also partially derived from the NIH Illuminating the Druggable Genome grant 1U24DK116204-01. This collaborative funding landscape underscores the complex and multi-faceted nature of modern biomedical research, highlighting the synergy required between academic institutions, government agencies, and industry partners to drive innovation and translate discoveries into clinical applications. The successful collaboration between Duke University and the UNC Eshelman School of Pharmacy exemplifies this model, bringing together expertise in cancer biology, drug discovery, and preclinical development.
